Fortress Biotech, Inc. SEC 10-Q Report

TradingView
2025.11.14 13:53
portai
I'm PortAI, I can summarize articles.

Fortress Biotech, Inc. released its Q3 2025 10-Q report, showing significant financial and operational improvements. Net revenue rose to $17.6 million, and net income reached $8.8 million, reversing a previous loss. Key drivers included increased product sales and strategic initiatives. The company expanded its market in China and launched new products, with plans for further development and growth. The report highlights enhanced profitability and operational efficiency.

Fortress Biotech, Inc., a biopharmaceutical company dedicated to acquiring, developing, and commercializing innovative pharmaceutical and biotechnology products, has released its Form 10-Q report for the third quarter of 2025. The report highlights significant improvements in both financial and operational performance, driven by increased product sales and strategic business initiatives.

Financial Highlights

Fortress Biotech, Inc. reported robust financial performance for the three months ended September 30, 2025, showcasing notable improvements across key metrics:

  • Net Revenue: $17.6 million, up from $14.6 million in the same period in 2024, driven by higher product sales.
  • Loss from Operations: $(6.8) million, a significant improvement from $(22.1) million in the same period in 2024, indicating enhanced operational efficiency.
  • Net Income: $8.8 million, compared to a net loss of $(26.7) million in the same period in 2024, primarily due to gains from the deconsolidation of a subsidiary.
  • Net Income Per Share - Basic: $0.13, compared to $(0.76) in the same period in 2024, reflecting improved profitability.
  • Net Income Per Share - Diluted: $0.11, compared to $(0.76) in the same period in 2024, highlighting the impact of potential share dilution.

Business Highlights

Fortress Biotech, Inc. also reported significant operational achievements during the third quarter of 2025:

  • Revenue Segments: The company saw substantial contributions from Journey Medical Corporation's dermatology products, including Amzeeq and Zilxi. Additionally, Journey began supplying Amzeeq to Cutia Therapeutics for commercial use in China, contributing to other revenue.
  • Geographical Performance: Journey Medical Corporation expanded its market presence in China through a licensing agreement with Cutia Therapeutics, which received marketing approval for Amzeeq in China. This approval triggered a milestone payment and commenced product supply to Cutia.
  • New Product Launches: Journey Medical Corporation launched Emrosi (Minocycline Hydrochloride Extended-Release Capsules, 40mg) for the treatment of rosacea, following FDA marketing approval in November 2024.
  • Future Outlook: The company anticipates continued development and commercialization of its existing and new product candidates. It plans to leverage strategic relationships and potential funding opportunities to support its operations and growth initiatives.

SEC Filing: Fortress Biotech, Inc. [ FBIO ] - 10-Q - Nov. 14, 2025

Source: TradingView The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
© 2025 Longbridge｜Disclaimer